Clinical Trial Update: Inflammatory Signal Inhibitors for COVID-19 (MATIS) [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion status of the MATIS inflammatory signal inhibitors trial for COVID-19 (Phase 1/2) conducted by Imperial College London.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia

Snippet

Sponsor: Imperial College London | Conditions: Coronavirus, Covid19 | Phase 1, Phase 2 | Status: COMPLETED